ReviewFrontiers in immunology2025
USP38: an important regulatory factor in tumor malignant progression.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- USP38 promotes breast cancer immune evasion and malignant progression by deubiquitinating and stabilizing PD-L1.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitin-Specific Protease 38 (USP38), a member of the deubiquitinating enzyme (DUB) family, exhibits a complex and context-dependent role in cancer progression. This review summarizes current research on USP38, highlighting its dual functionality as both an oncogene and a tumor suppressor in various malignancies. We detail the structural characteristics of USP38, its differential expression patterns across cancer types, and its impact on key cellular processes including proliferation, migration, invasion, and apoptosis. Mechanistically, USP38 regulates the stability and activity of crucial proteins involved in tumorigenesis, such as HDAC1/3, LSD1, KLF5, METTL14, c-Myc, and HIF-1α, as well as influencing signaling pathways like JAK2/STAT3. The intricate interplay and, in some instances feedback loops, between USP38 and its targets underscore its multifaceted role. Finally, we discuss the potential of USP38 as a therapeutic target, the challenges in developing specific inhibitors, and future research directions to fully elucidate its complex biology and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.